Home/PharmaEssentia/Lih-Ling Lin

LL

Lih-Ling Lin

Chief Scientific Officer

Therapeutic Areas

Hematologic Oncology Oncology

PharmaEssentia Pipeline

Drug	Indication	Phase
Ropeginterferon alfa-2b (BESREMi®)	Polycythemia Vera (PV)	Approved
Ropeginterferon alfa-2b	Essential Thrombocythemia (ET)	Phase III
KX01 (Tirbanibulin)	Gastric/Gastro-esophageal/Esophageal Cancers	Phase I

Leadership Team at PharmaEssentia

Founder and CEO

Ching-Leou Teng

Cheng-Ku (Jack) Hwang

General Manager, HQ

Chief Medical Officer

Representative Director & General Manager of Japan Operations

View full PharmaEssentia profile